https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1?s=08 https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1?... Here's the original study. The

https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1?s=08 https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1?... Here's the original study. The folks who performed the study have existing COVID-19 vaccine patents. The study (perhaps conveniently for the patent holders) only tests whether "boosting" with Omicron specific vaccines would provide a benefit to those subjects who already received 2 doses of mRNA-1273 (eg. Moderna). They didn't test how effective the mRNA-1273.529 (Omicron) specific vaccines were when given to the subjects on their own (at least not in this study).